Abnormalities of the oculomotor function in type 1 diabetes and diabetic neuropathy

Aims Abnormalities in the oculomotor system may represent an early sign of diabetic neuropathy and are currently poorly studied. We designed an eye-tracking-based test to evaluate oculomotor function in patients with type 1 diabetes. Methods We used the SRLab—Tobii TX300 Eye tracker® , an eye-tracki...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Acta diabetologica 2022-09, Vol.59 (9), p.1157-1167
Hauptverfasser: D’Addio, Francesca, Pastore, Ida, Loretelli, Cristian, Valderrama-Vasquez, Alessandro, Usuelli, Vera, Assi, Emma, Mameli, Chiara, Macedoni, Maddalena, Maestroni, Anna, Rossi, Antonio, Lunati, Maria Elena, Morpurgo, Paola Silvia, Gandolfi, Alessandra, Montefusco, Laura, Bolla, Andrea Mario, Ben Nasr, Moufida, Di Maggio, Stefania, Melzi, Lisa, Staurenghi, Giovanni, Secchi, Antonio, Bianchi Marzoli, Stefania, Zuccotti, Gianvincenzo, Fiorina, Paolo
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Aims Abnormalities in the oculomotor system may represent an early sign of diabetic neuropathy and are currently poorly studied. We designed an eye-tracking-based test to evaluate oculomotor function in patients with type 1 diabetes. Methods We used the SRLab—Tobii TX300 Eye tracker® , an eye-tracking device, coupled with software that we developed to test abnormalities in the oculomotor system. The software consists of a series of eye-tracking tasks divided into 4 classes of parameters (Resistance, Wideness, Pursuit and Velocity) to evaluate both smooth and saccadic movement in different directions. We analyzed the oculomotor system in 34 healthy volunteers and in 34 patients with long-standing type 1 diabetes. Results Among the 474 parameters analyzed with the eye-tracking-based system, 11% were significantly altered in patients with type 1 diabetes ( p  
ISSN:1432-5233
0940-5429
1432-5233
DOI:10.1007/s00592-022-01911-1